MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
0.1656
-0.0094
-5.37%
After Hours: 0.1779 +0.0123 +7.43% 19:53 06/08 EDT
OPEN
0.1790
PREV CLOSE
0.1750
HIGH
0.1790
LOW
0.1640
VOLUME
14.27M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.1626
MARKET CAP
38.87M
P/E (TTM)
-0.2115
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GOSS last week (0601-0605)?
Weekly Report · 1d ago
Gossamer Bio shareholders reaffirm board and governance structure
TipRanks · 4d ago
Gossamer Bio Restructures Capital Through Convertible Notes Exchange
TipRanks · 4d ago
Gossamer Bio shareholders re-elect Hasnain, Cox to board as Class II directors
PUBT · 4d ago
Gossamer Bio announces early tender results, early settlement of solicitation
TipRanks · 6d ago
Gossamer Bio accepts $181.05 million early tenders in convertible notes exchange offer
PUBT · 6d ago
GOSSAMER BIO, INC. ANNOUNCES EARLY TENDER RESULTS AND EARLY SETTLEMENT FOR EXCHANGE OFFER AND CONSENT SOLICITATION WITH RESPECT TO EXISTING CONVERTIBLE NOTES
Reuters · 6d ago
Gossamer Bio announces extension of early tender date for exchange offer
TipRanks · 06/02 13:07
More
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.